ROS kinase fusions are not common in Chinese patients with cholangiocarcinoma.

Abstract

OBJECTIVE: To investigate the expressions of different forms of ROS fusions in Chinese patients with cholangiocarcinoma (CCA). METHODS: RT-PCR was employed to examine formalin-fixed and paraffin-embedded CCA samples from stage I-IV patients for detection of ROS fusions involving Fused in Glioblastoma (FIG), solute carrier protein (SLC34A2) and major histocompatibility complex class II invariant chain (CD74). Serpin peptidase inhibitor clade A member 1 (SERPINA1) was detected as the reference gene. RESULTS: In all the 56 CCA samples, 80.4% (45/56) were positive for SERPINA1 expression as evaluable samples. Of these evaluable samples, none expressed the ROS fusions. CONCLUSION: ROS fusions are not common in Chinese CCA patients.